MiMedx Group (MDXG) Financials

$6.98 +0.02 (+0.22%)

As of 10:25 AM Eastern

Annual Income Statements for MiMedx Group

This table shows MiMedx Group's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	6.22	29	0.39	65	-30	-26	-83	-29	-30	58	42
Consolidated Net Income / (Loss)	6.22	29	0.39	65	-30	-26	-49	-10	-30	58	42
Net Income / (Loss) Continuing Operations	6.22	29	0.39	65	-30	-26	-49	-12	-20	67	42
Total Pre-Tax Income	7.05	24	0.55	45	-3.40	-26	-62	-12	-20	31	57
Total Operating Income	7.10	24	0.88	46	-3.92	-21	-45	-7.05	-15	37	59
Total Gross Profit	106	167	191	286	323	256	209	202	220	267	289
Total Revenue	118	187	222	321	359	299	248	242	268	321	349
Operating Revenue	118	187	222	321	359	299	248	242	268	321	349
Total Cost of Revenue	13	20	31	35	36	43	39	40	48	55	60
Operating Cost of Revenue	13	20	31	35	36	43	39	40	48	55	60
Total Operating Expenses	98	143	190	240	327	277	254	209	234	230	230
Selling, General & Admin Expense	90	133	173	220	259	198	181	195	209	211	225
Research & Development Expense	7.05	8.41	14	18	16	11	12	9.93	13	13	12
Amortization Expense	0.93	0.93	2.14	1.68	1.03	1.04	1.07	0.82	0.70	0.76	0.77
Other Operating Expenses / (Income)	-	-	0.00	0.00	51	67	59	3.79	12	5.18	-8.70
Impairment Charge	-	-	-	0.00	0.00	0.45	1.03	0.05	0.00	0.00	0.45
Total Other Income / (Expense), net	-0.05	-0.09	-0.34	-1.14	0.53	-4.43	-16	-5.00	-5.02	-6.48	-1.57
Interest & Investment Income	-	-	-	-	-	-	-	-	-5.02	-6.46	-1.01
Other Income / (Expense), net	-	-	-0.34	-1.05	0.00	0.28	-0.00	-0.02	-0.00	-0.03	-0.57
Income Tax Expense	0.83	-5.17	0.16	-20	27	-0.01	-12	0.25	0.21	-37	15
Net Income / (Loss) Discontinued Operations	-	-	-	-	-	-	-	2.02	-10	-9.21	0.42
Basic Earnings per Share	$0.06	$0.28	$0.00	$0.61	($0.28)	($0.24)	($0.77)	($0.15)	($0.33)	$0.40	$0.29
Weighted Average Basic Shares Outstanding	105.79M	105.93M	105.93M	106.12M	105.60M	106.95M	108.26M	110.35M	112.91M	116.50M	146.98M
Diluted Earnings per Share	$0.05	$0.26	$0.00	$0.56	($0.28)	($0.24)	($0.77)	($0.15)	($0.33)	$0.37	$0.28
Weighted Average Diluted Shares Outstanding	113.30M	113.63M	112.65M	116.11M	105.60M	106.95M	108.26M	110.35M	112.91M	145.96M	149.05M
Weighted Average Basic & Diluted Shares Outstanding	103.70M	107.81M	108.84M	106.10M	107.10M	106.60M	111.26M	112.36M	114.08M	146.96M	147.37M

This table shows MiMedx Group's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025
Net Income / (Loss) Attributable to Common Shareholders	2.80	-8.61	8.72	16	43	9.26	18	16	-9.50	7.02	9.62
Consolidated Net Income / (Loss)	-0.41	-4.98	1.20	8.53	53	9.26	18	8.10	7.44	7.02	9.62
Net Income / (Loss) Continuing Operations	9.83	-1.94	9.25	8.84	51	9.06	18	7.88	7.44	7.02	9.62
Total Pre-Tax Income	9.86	-1.89	9.18	9.43	14	11	23	11	11	8.61	13
Total Operating Income	11	-0.34	11	11	15	13	23	11	11	8.25	12
Total Gross Profit	60	59	68	67	73	72	72	69	76	72	80
Total Revenue	74	72	81	82	87	85	87	84	93	88	99
Operating Revenue	74	72	81	82	87	85	87	84	93	88	99
Total Cost of Revenue	14	12	14	15	14	13	15	15	17	17	19
Operating Cost of Revenue	14	12	14	15	14	13	15	15	17	17	19
Total Operating Expenses	49	60	57	56	57	59	49	58	65	63	68
Selling, General & Admin Expense	50	52	52	53	54	55	55	54	61	60	64
Research & Development Expense	-4.73	3.48	3.67	3.08	2.43	2.84	3.01	2.92	3.57	3.33	3.30
Amortization Expense	0.18	0.19	0.19	0.19	0.19	0.19	0.19	0.19	0.19	0.10	0.10
Other Operating Expenses / (Income)	3.41	3.67	1.02	-0.04	0.52	0.31	-9.70	0.65	0.04	0.00	0.00
Impairment Charge	-	0.00	0.00	0.00	-	0.05	0.00	0.30	0.09	0.00	0.00
Total Other Income / (Expense), net	-1.45	-1.55	-1.66	-1.69	-1.58	-1.79	-0.23	0.26	0.20	0.36	0.64
Interest & Investment Income	-	-	-1.63	-1.68	-	-1.69	0.00	0.28	-	0.51	0.74
Other Income / (Expense), net	-0.00	0.00	-0.03	-0.01	0.02	-0.10	-0.24	-0.02	-0.21	-0.15	-0.10
Income Tax Expense	0.03	0.05	-0.07	0.59	-37	2.35	5.60	3.54	3.81	1.59	3.39
Net Income / (Loss) Discontinued Operations	-	-3.04	-8.05	-0.31	2.19	0.20	0.00	0.22	-	0.00	0.00
Basic Earnings per Share	($0.02)	($0.06)	$0.00	$0.06	$0.40	$0.06	$0.12	$0.05	$0.06	$0.05	$0.07
Weighted Average Basic Shares Outstanding	112.91M	114.40M	115.87M	116.30M	116.50M	146.40M	147.33M	146.96M	146.98M	147.27M	147.76M
Diluted Earnings per Share	($0.02)	($0.06)	$0.01	$0.06	$0.36	$0.06	$0.12	$0.05	$0.05	$0.05	$0.06
Weighted Average Diluted Shares Outstanding	112.91M	114.40M	146.86M	149.77M	145.96M	150.03M	148.90M	148.37M	149.05M	149.68M	149.32M
Weighted Average Basic & Diluted Shares Outstanding	114.08M	115.60M	116.11M	116.38M	146.96M	147.60M	146.81M	146.95M	147.37M	147.70M	147.96M

This table details how cash moves in and out of MiMedx Group's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	2.50	-18	4.02	-2.85	18	24	27	-8.73	-21	16	22
Net Cash From Operating Activities	17	19	24	63	36	-39	-30	-1.98	-18	27	66
Net Cash From Continuing Operating Activities	17	19	24	63	36	-39	-30	-9.87	-7.97	35	67
Net Income / (Loss) Continuing Operations	6.22	29	0.39	65	-30	-26	-49	-12	-20	67	42
Depreciation Expense	1.20	1.80	3.33	4.09	5.88	6.55	5.78	4.36	3.35	2.67	2.28
Amortization Expense	0.93	0.98	2.29	1.84	0.98	2.47	3.35	1.88	0.70	0.76	3.76
Non-Cash Adjustments To Reconcile Net Income	11	17	19	23	15	-2.80	26	16	15	20	11
Changes in Operating Assets and Liabilities, net	-3.00	-30	-1.38	-31	44	-20	-16	-19	-7.47	-56	8.15
Net Cash From Discontinued Operating Activities	-	-	-	-	-	-	-	7.89	-9.92	-8.16	-0.93
Net Cash From Investing Activities	-12	-0.68	-12	-5.40	-9.22	0.50	-4.56	-3.40	-2.66	-2.16	-9.58
Net Cash From Continuing Investing Activities	-12	-0.68	-12	-5.40	-9.22	0.50	-4.56	-3.40	-2.66	-2.16	-9.58
Purchase of Property, Plant & Equipment	-2.56	-5.83	-6.21	-5.13	-9.42	-1.75	-4.23	-3.22	-1.51	-1.99	-1.68
Acquisitions	0.00	0.00	-7.63	-	-0.61	-0.47	-0.33	0.00	0.00	0.00	-7.86
Other Investing Activities, net	-0.59	-0.85	-0.84	-0.27	-	-	-	-0.25	-1.15	-0.17	-0.04
Net Cash From Financing Activities	-2.15	-36	-8.15	-60	-8.93	63	62	-3.35	-0.58	-8.57	-34
Net Cash From Continuing Financing Activities	-2.15	-36	-8.15	-60	-8.93	63	62	-3.35	-0.58	-8.57	-34
Repayment of Debt	0.00	-0.50	-	-0.03	-0.00	-8.53	-89	-	-0.04	-0.05	-82
Repurchase of Common Equity	-5.61	-40	-10	-68	-7.57	0.00	-7.47	0.00	0.00	-9.52	0.00
Issuance of Debt	-	-	-	0.00	0.00	73	60	-	0.00	0.00	50
Other Financing Activities, net	3.47	4.56	2.23	7.91	-1.36	-1.37	-1.92	-3.35	-0.54	1.00	-2.24

This table details how cash moves in and out of MiMedx Group's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025
Net Change in Cash & Equivalents	-7.27	-4.73	7.43	13	0.84	-34	21	20	16	2.02	12
Net Cash From Operating Activities	-5.62	-4.05	7.78	13	10	5.98	22	20	19	5.30	14
Net Cash From Continuing Operating Activities	4.30	0.60	12	13	9.27	6.79	22	20	19	5.30	14
Net Income / (Loss) Continuing Operations	9.83	-1.94	9.25	8.84	51	9.06	18	7.88	7.44	7.02	9.62
Depreciation Expense	0.80	0.71	0.69	0.65	0.61	0.75	0.58	0.58	0.56	3.20	3.17
Non-Cash Adjustments To Reconcile Net Income	0.81	4.20	4.93	5.14	5.41	6.46	-4.87	4.21	5.13	5.34	5.39
Changes in Operating Assets and Liabilities, net	-6.97	-2.68	-2.97	-2.10	-48	-9.56	8.11	6.16	3.44	-10	-3.62
Net Cash From Investing Activities	-1.71	-0.68	-0.35	-0.65	-0.48	-6.02	-0.91	0.11	-2.77	-0.41	-0.89
Net Cash From Continuing Investing Activities	-1.71	-0.68	-0.35	-0.65	-0.48	-6.02	-0.91	0.11	-2.77	-0.41	-0.89
Purchase of Property, Plant & Equipment	-0.67	-0.63	-0.30	-0.63	-0.43	-1.14	-0.47	-0.17	5.10	-0.38	-0.18
Acquisitions	-	-	-	-	-	-5.00	-	-	-	0.00	-0.74
Net Cash From Financing Activities	0.07	-0.00	0.00	0.37	-8.94	-33	-0.36	0.03	-0.40	-2.88	-1.09
Net Cash From Continuing Financing Activities	0.07	-0.00	0.00	0.37	-8.94	-33	-0.36	0.03	-0.40	-2.88	-1.09
Other Financing Activities, net	0.11	-0.00	0.00	0.37	0.63	-1.65	-0.36	0.78	-1.01	-2.88	-1.09

This table presents MiMedx Group's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	109	136	117	121	123	167	202	188	171	239	264
Total Current Assets	86	96	59	49	74	123	161	149	134	164	192
Cash & Equivalents	47	28	30	27	45	69	96	87	66	82	104
Accounts Receivable	27	54	-	-	0.00	32	35	40	43	54	56
Inventories, net	5.13	7.46	16	9.47	16	9.10	10	11	13	21	24
Prepaid Expenses	1.54	3.39	1.84	2.13	6.67	6.67	5.61	6.15	7.32	5.62	5.02
Other Current Assets	-	0.22	9.52	9.02	5.82	6.06	3.37	2.81	3.34	1.75	2.82
Plant, Property, & Equipment, net	5.45	9.48	14	14	17	12	0.00	9.17	7.86	6.97	5.94
Total Noncurrent Assets	18	30	44	58	31	32	41	30	29	68	66
Goodwill	4.04	4.04	20	20	20	20	20	20	19	19	19
Intangible Assets	11	11	23	10	9.61	7.78	6.00	5.38	5.85	5.26	12
Noncurrent Deferred & Refundable Income Taxes	0.00	15	0.00	26	-	-	-	-	0.00	41	28
Other Noncurrent Operating Assets	3.25	0.49	0.35	2.87	1.79	3.84	15	4.88	3.55	2.34	6.71
Total Liabilities & Shareholders' Equity	109	136	117	121	123	167	202	188	171	239	264
Total Liabilities	20	28	69	47	73	133	111	95	97	96	71
Total Current Liabilities	18	27	61	46	72	67	59	42	44	46	46
Short-Term Debt	-	0.00	-	-	0.00	3.75	-	-	-	1.00	1.00
Accounts Payable	3.66	6.63	12	8.45	15	8.71	8.77	7.39	8.45	9.05	7.41
Accrued Expenses	2.50	4.64	19	16	32	32	30	9.81	11	9.36	9.01
Current Employee Benefit Liabilities	12	15	13	21	23	21	18	24	21	22	24
Other Current Liabilities	0.72	0.53	1.48	0.65	1.82	1.40	1.47	1.57	1.83	2.89	4.51
Total Noncurrent Liabilities	1.53	1.15	0.88	1.65	1.64	65	51	53	53	50	25
Long-Term Debt	-	-	-	-	0.00	62	48	48	49	48	18
Other Noncurrent Operating Liabilities	1.53	1.15	0.88	1.65	1.64	3.54	3.76	4.87	4.77	2.22	7.38
Total Equity & Noncontrolling Interests	89	108	48	74	50	34	-0.15	0.08	-18	143	193
Total Preferred & Common Equity	89	108	48	74	50	34	-0.15	0.08	-18	143	193
Total Common Equity	89	108	48	74	50	34	-0.15	0.08	-18	143	193
Common Stock	163	163	162	165	165	147	159	166	174	276	284
Retained Earnings	-68	-38	-111	-47	-77	-102	-151	-162	-192	-134	-91

This table presents MiMedx Group's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2022	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025
Period end date	6/30/2022	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025
Total Assets	169	173	168	176	189	222	230	244	270	291
Total Current Assets	131	136	132	141	155	139	154	172	200	221
Cash & Equivalents	73	73	61	69	81	48	69	89	106	119
Accounts Receivable	38	41	45	49	49	57	53	54	62	69
Inventories, net	13	14	15	17	19	24	25	24	24	25
Prepaid Expenses	4.09	4.68	8.82	3.68	2.95	6.10	4.03	2.91	5.35	4.86
Other Current Assets	2.57	2.58	2.31	3.11	2.31	2.80	3.10	2.15	1.97	3.03
Plant, Property, & Equipment, net	0.00	7.91	7.56	7.26	7.09	7.34	6.82	6.45	5.77	5.39
Total Noncurrent Assets	38	29	29	28	27	75	69	65	65	65
Goodwill	20	20	20	19	19	19	19	19	19	19
Intangible Assets	5.14	4.99	5.71	5.57	5.40	13	12	11	11	12
Noncurrent Deferred & Refundable Income Taxes	-	-	-	-	-	39	33	31	28	27
Other Noncurrent Operating Assets	13	3.88	3.21	2.89	2.59	4.75	4.41	4.02	6.35	5.98
Total Liabilities & Shareholders' Equity	169	173	168	176	189	222	230	244	270	291
Total Liabilities	90	100	94	97	95	66	62	63	68	74
Total Current Liabilities	37	46	41	44	44	42	40	42	43	50
Short-Term Debt	-	-	-	-	-	1.00	3.20	3.86	1.13	1.25
Accounts Payable	8.08	8.82	7.82	8.15	9.17	9.70	7.60	6.92	8.87	8.50
Accrued Expenses	10	11	13	13	9.44	9.20	9.28	8.40	9.45	15
Current Employee Benefit Liabilities	17	24	18	22	23	18	18	20	19	22
Other Current Liabilities	1.78	1.96	1.79	2.06	1.85	4.07	2.07	2.59	4.44	3.41
Total Noncurrent Liabilities	53	54	53	52	52	24	22	21	25	24
Long-Term Debt	48	48	49	49	49	18	18	18	18	17
Other Noncurrent Operating Liabilities	4.28	5.49	4.03	3.25	2.61	5.28	3.88	2.92	7.49	6.98
Total Equity & Noncontrolling Interests	-14	-20	-18	-13	1.33	156	168	181	203	217
Total Preferred & Common Equity	-14	-20	-18	-13	1.33	156	168	181	203	217
Total Common Equity	-14	-20	-18	-13	1.33	156	168	181	203	217
Common Stock	169	172	179	183	188	280	275	280	287	291
Retained Earnings	-183	-191	-197	-196	-187	-124	-107	-99	-84	-75

This table displays calculated financial ratios and metrics derived from MiMedx Group's official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	99.77%	58.43%	18.38%	44.85%	11.82%	-16.67%	-17.05%	-2.50%	10.67%	20.03%	8.52%
EBITDA Growth	2,327.63%	194.18%	-77.28%	728.80%	-94.25%	-503.57%	-205.79%	97.70%	-1,178.11%	479.20%	58.80%
EBIT Growth	369.04%	243.15%	-97.76%	8,188.99%	-108.69%	-432.03%	-117.47%	84.42%	-108.24%	351.78%	57.19%
NOPAT Growth	439.00%	371.87%	-97.86%	10,389.68%	-104.14%	-439.25%	-114.55%	84.47%	-108.86%	892.63%	-47.19%
Net Income Growth	251.26%	373.41%	-98.68%	16,496.67%	-146.32%	14.67%	-92.67%	79.13%	-193.60%	292.83%	-27.15%
EPS Growth	225.00%	420.00%	-100.00%	0.00%	-150.00%	14.29%	-220.83%	80.52%	-120.00%	212.12%	-24.32%
Operating Cash Flow Growth	6,016.20%	11.93%	26.81%	163.91%	-43.13%	-210.10%	23.21%	93.45%	-802.78%	249.64%	147.24%
Free Cash Flow Firm Growth	91.16%	-699.79%	489.52%	50.60%	-33.15%	-205.69%	-6.87%	65.41%	11.81%	302.99%	66.17%
Invested Capital Growth	25.46%	106.78%	-49.86%	20.76%	-90.21%	582.94%	39.75%	23.83%	5.86%	95.85%	-2.00%
Revenue Q/Q Growth	22.33%	7.01%	-2.32%	14.62%	1.42%	-5.13%	-3.07%	-6.83%	9.65%	4.03%	1.77%
EBITDA Q/Q Growth	200.17%	14.14%	-72.87%	121.16%	-90.22%	27.55%	-47.84%	95.21%	46.79%	9.55%	-4.21%
EBIT Q/Q Growth	585.33%	14.57%	-96.88%	161.96%	-116.27%	16.69%	-32.87%	71.04%	40.49%	12.77%	-7.40%
NOPAT Q/Q Growth	520.22%	48.30%	-96.88%	259.75%	-105.58%	16.13%	-32.82%	71.14%	40.50%	153.79%	-52.39%
Net Income Q/Q Growth	547.30%	47.97%	-98.04%	172.53%	-172.91%	52.92%	-22.66%	64.63%	-9.54%	1,242.59%	-52.05%
EPS Q/Q Growth	400.00%	44.44%	-100.00%	180.00%	-177.78%	52.94%	-14.93%	54.55%	-10.00%	3,800.00%	-52.54%
Operating Cash Flow Q/Q Growth	79.57%	-17.28%	76.61%	10.86%	-35.07%	-167.09%	29.81%	78.02%	-15.43%	145.78%	14.78%
Free Cash Flow Firm Q/Q Growth	64.61%	-1,115.28%	193.69%	115.67%	-74.84%	-42.09%	19.18%	20.49%	37.33%	45.23%	18.85%
Invested Capital Q/Q Growth	8.80%	44.48%	-66.52%	-56.28%	0.00%	172.35%	3.08%	21.60%	17.69%	80.39%	-4.51%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	89.29%	89.21%	86.05%	89.03%	89.87%	85.60%	84.16%	83.63%	81.96%	83.01%	82.78%
EBITDA Margin	7.80%	14.49%	2.78%	15.91%	0.82%	-3.96%	-14.61%	-0.35%	-3.99%	12.60%	18.44%
Operating Margin	6.01%	13.01%	0.40%	14.39%	-1.09%	-7.07%	-18.29%	-2.91%	-5.50%	11.55%	16.87%
EBIT Margin	6.01%	13.01%	0.25%	14.07%	-1.09%	-6.98%	-18.29%	-2.92%	-5.50%	11.54%	16.71%
Profit (Net Income) Margin	5.26%	15.72%	0.18%	20.16%	-8.35%	-8.55%	-19.85%	-4.25%	-11.27%	18.11%	12.16%
Tax Burden Percent	88.20%	121.29%	71.56%	143.56%	882.51%	99.98%	80.08%	85.32%	152.92%	190.08%	74.04%
Interest Burden Percent	99.32%	99.65%	100.00%	99.81%	86.57%	122.55%	135.55%	170.40%	134.05%	82.59%	98.27%
Effective Tax Rate	11.80%	-21.29%	28.44%	-43.56%	0.00%	0.00%	0.00%	0.00%	0.00%	-120.15%	26.70%
Return on Invested Capital (ROIC)	18.84%	52.07%	1.10%	156.72%	-10.80%	-83.40%	-85.56%	-10.18%	-18.68%	97.32%	39.21%
ROIC Less NNEP Spread (ROIC-NNEP)	18.93%	52.32%	2.28%	165.49%	64.22%	-39.02%	-17.61%	2.10%	51.47%	192.60%	40.47%
Return on Net Nonoperating Assets (RNNOA)	-11.20%	-22.23%	-0.60%	-50.49%	-37.77%	22.53%	7.21%	-0.99%	-17.47%	-43.70%	-13.94%
Return on Equity (ROE)	7.64%	29.85%	0.50%	106.23%	-48.57%	-60.87%	-78.34%	-11.18%	-36.15%	53.61%	25.26%
Cash Return on Invested Capital (CROIC)	-3.74%	-17.54%	67.52%	137.92%	153.51%	-232.31%	-118.72%	-31.47%	-24.37%	32.52%	41.23%
Operating Return on Assets (OROA)	7.32%	19.88%	0.43%	37.88%	-3.22%	-14.40%	-24.59%	-3.63%	-8.20%	18.07%	23.18%
Return on Assets (ROA)	6.41%	24.02%	0.31%	54.27%	-24.56%	-17.64%	-26.70%	-5.27%	-16.81%	28.37%	16.87%
Return on Common Equity (ROCE)	7.64%	29.85%	0.50%	106.23%	-48.57%	-60.87%	-21.33%	0.00%	3.87%	30.78%	25.26%
Return on Equity Simple (ROE_SIMPLE)	6.96%	27.27%	0.81%	87.71%	-60.37%	-74.36%	0.00%	0.00%	167.87%	40.80%	21.97%
Net Operating Profit after Tax (NOPAT)	6.26	30	0.63	66	-2.75	-15	-32	-4.94	-10	82	43
NOPAT Margin	5.30%	15.78%	0.29%	20.66%	-0.76%	-4.95%	-12.80%	-2.04%	-3.85%	25.42%	12.37%
Net Nonoperating Expense Percent (NNEP)	-0.09%	-0.25%	-1.18%	-8.76%	-75.03%	-44.38%	-67.95%	-12.29%	-70.15%	-95.28%	-1.26%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-33.68%	42.60%	20.22%
Cost of Revenue to Revenue	10.71%	10.79%	13.95%	10.97%	10.13%	14.40%	15.84%	16.37%	18.04%	16.99%	17.22%
SG&A Expenses to Revenue	76.53%	71.22%	78.22%	68.54%	71.99%	66.23%	72.92%	80.51%	77.91%	65.67%	64.52%
R&D to Revenue	5.96%	4.49%	6.47%	5.57%	4.39%	3.72%	4.72%	4.10%	4.74%	3.94%	3.54%
Operating Expenses to Revenue	83.28%	76.21%	85.65%	74.64%	90.96%	92.67%	102.44%	86.54%	87.46%	71.46%	65.91%
Earnings before Interest and Taxes (EBIT)	7.10	24	0.55	45	-3.92	-21	-45	-7.07	-15	37	58
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	9.23	27	6.17	51	2.94	-12	-36	-0.84	-11	41	64
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	13.80	9.45	20.19	18.97	5.39	24.47	0.00	8,260.40	0.00	7.15	7.32
Price to Tangible Book Value (P/TBV)	16.56	10.96	210.66	31.98	13.33	126.66	0.00	0.00	0.00	8.65	8.72
Price to Revenue (P/Rev)	10.43	5.45	4.38	4.36	0.75	2.81	4.06	2.80	1.18	3.17	4.05
Price to Earnings (P/E)	198.23	34.67	2,487.95	21.63	0.00	0.00	0.00	0.00	0.00	17.53	33.33
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.50%	2.88%	0.04%	4.62%	0.00%	0.00%	0.00%	0.00%	0.00%	5.71%	3.00%
Enterprise Value to Invested Capital (EV/IC)	31.91	12.93	24.50	29.63	49.04	27.05	24.29	13.63	6.89	8.88	12.20
Enterprise Value to Revenue (EV/Rev)	9.99	5.28	4.24	4.27	0.62	2.80	4.24	3.02	1.46	3.07	3.81
Enterprise Value to EBITDA (EV/EBITDA)	127.99	36.46	152.45	26.86	75.70	0.00	0.00	0.00	0.00	24.38	20.66
Enterprise Value to EBIT (EV/EBIT)	166.29	40.61	1,724.73	30.39	0.00	0.00	0.00	0.00	0.00	26.63	22.80
Enterprise Value to NOPAT (EV/NOPAT)	188.53	33.49	1,485.93	20.69	0.00	0.00	0.00	0.00	0.00	12.09	30.81
Enterprise Value to Operating Cash Flow (EV/OCF)	70.27	52.61	39.41	21.81	6.22	0.00	0.00	0.00	0.00	36.89	20.08
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	24.24	23.51	5.70	0.00	0.00	0.00	0.00	36.17	29.30
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	1.91	0.52	0.52	0.65	0.34	0.10
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	1.80	0.52	0.52	0.65	0.34	0.09
Financial Leverage	-0.59	-0.42	-0.26	-0.31	-0.59	-0.58	-0.41	-0.47	-0.34	-0.23	-0.34
Leverage Ratio	1.19	1.24	1.62	1.96	1.98	3.45	2.93	2.12	2.15	1.89	1.50
Compound Leverage Factor	1.18	1.24	1.62	1.95	1.71	4.23	3.98	3.61	2.88	1.56	1.47
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	65.62%	34.29%	34.20%	39.48%	25.60%	9.49%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	3.75%	0.00%	0.00%	0.00%	0.52%	1.13%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	61.87%	34.29%	34.20%	39.48%	25.08%	8.36%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	65.82%	65.74%	75.14%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	34.38%	-0.11%	0.06%	-14.61%	74.40%	90.51%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	-5.54	-1.32	-57.57	-4.55	1.21	0.31
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.29	1.33	46.60	1.62	-0.81	-1.31
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	-5.22	-1.32	-57.57	-4.55	1.19	0.28
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	-4.43	-1.50	-9.75	-4.71	0.60	0.47
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.23	1.51	7.89	1.68	-0.40	-1.95
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	-4.18	-1.50	-9.75	-4.71	0.59	0.41
Altman Z-Score	38.29	24.13	8.98	21.07	4.16	4.73	5.51	4.90	2.30	8.02	14.21
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	72.78%	100.04%	110.72%	42.58%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.66	3.60	0.98	1.06	1.04	1.83	2.71	3.51	3.08	3.57	4.21
Quick Ratio	4.29	3.18	0.50	0.60	0.63	1.51	2.22	3.01	2.50	2.95	3.51
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-1.24	-9.95	39	58	39	-41	-44	-15	-13	27	45
Operating Cash Flow to CapEx	656.84%	322.76%	384.35%	1,227.84%	381.25%	-2,249.54%	-715.78%	-61.59%	-1,181.84%	1,347.51%	3,933.33%
Free Cash Flow to Firm to Interest Expense	-25.93	-115.75	0.00	671.20	0.00	-8.76	-2.73	-3.06	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	350.04	218.69	0.00	723.44	0.00	-8.37	-1.87	-0.40	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	296.75	150.93	0.00	664.52	0.00	-8.74	-2.14	-1.04	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.22	1.53	1.75	2.69	2.94	2.06	1.34	1.24	1.49	1.57	1.39
Accounts Receivable Turnover	5.53	4.66	0.00	0.00	0.00	0.00	7.33	6.39	6.42	6.63	6.36
Inventory Turnover	2.81	3.21	2.65	2.78	2.86	3.43	4.04	3.64	3.93	3.19	2.68
Fixed Asset Turnover	24.80	25.10	18.90	22.88	22.79	20.12	0.00	0.00	31.47	43.36	54.01
Accounts Payable Turnover	4.12	3.93	3.25	3.38	3.12	3.66	4.50	4.91	6.10	6.24	7.30
Days Sales Outstanding (DSO)	66.02	78.37	0.00	0.00	0.00	0.00	49.81	57.14	56.85	55.04	57.38
Days Inventory Outstanding (DIO)	129.89	113.76	137.63	131.30	127.66	106.29	90.32	100.17	92.81	114.26	136.19
Days Payable Outstanding (DPO)	88.65	92.99	112.34	108.12	116.96	99.86	81.09	74.38	59.83	58.46	50.00
Cash Conversion Cycle (CCC)	107.26	99.14	25.29	23.18	10.71	6.42	59.04	82.93	89.84	110.83	143.57
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	37	77	38	46	4.54	31	43	54	57	111	109
Invested Capital Turnover	3.56	3.30	3.86	7.58	14.12	16.85	6.68	4.99	4.85	3.83	3.17
Increase / (Decrease) in Invested Capital	7.51	40	-38	7.96	-42	26	12	10	3.14	54	-2.23
Enterprise Value (EV)	1,181	989	940	1,373	222	838	1,052	731	391	988	1,329
Market Capitalization	1,233	1,021	970	1,400	268	842	1,008	677	316	1,021	1,414
Book Value per Share	$0.84	$0.99	$0.44	$0.66	$0.45	$0.31	$0.00	$0.00	($0.16)	$1.23	$1.31
Tangible Book Value per Share	$0.70	$0.86	$0.04	$0.39	$0.18	$0.06	($0.24)	($0.23)	($0.38)	$1.01	$1.10
Total Capital	89	108	48	74	50	100	139	141	123	192	213
Total Debt	0.00	0.00	0.00	0.00	0.00	66	48	48	49	49	20
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	62	48	48	49	48	18
Net Debt	-52	-31	-30	-27	-45	-3.41	-48	-39	-17	-33	-84
Capital Expenditures (CapEx)	2.56	5.83	6.21	5.13	9.39	1.75	4.23	3.22	1.51	1.99	1.68
Debt-free, Cash-free Net Working Capital (DFCFNWC)	15	38	-32	-25	-43	-9.40	5.64	19	25	37	44
Debt-free Net Working Capital (DFNWC)	67	70	-1.32	2.94	2.50	60	101	106	91	119	149
Net Working Capital (NWC)	67	70	-1.32	2.94	2.50	56	101	106	91	118	146
Net Nonoperating Expense (NNE)	0.04	0.10	0.24	1.63	27	11	18	5.35	20	23	0.73
Net Nonoperating Obligations (NNO)	-52	-31	-9.71	-27	-45	-3.41	-48	-39	-18	-32	-84
Total Depreciation and Amortization (D&A)	2.13	2.77	5.62	5.93	6.86	9.02	9.13	6.24	4.05	3.43	6.04
Debt-free, Cash-free Net Working Capital to Revenue	12.64%	20.31%	-14.27%	-7.64%	-11.87%	-3.14%	2.27%	7.88%	9.22%	11.59%	12.70%
Debt-free Net Working Capital to Revenue	56.90%	37.12%	-0.59%	0.91%	0.70%	19.94%	40.87%	43.87%	33.84%	37.10%	42.63%
Net Working Capital to Revenue	56.90%	37.12%	-0.59%	0.91%	0.70%	18.69%	40.87%	43.87%	33.84%	36.78%	41.93%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.06	$0.28	$0.11	$0.61	($0.28)	($0.24)	($0.77)	($0.15)	($0.33)	$0.40	$0.29
Adjusted Weighted Average Basic Shares Outstanding	105.79M	105.93M	105.93M	106.12M	105.60M	106.95M	108.26M	110.35M	112.91M	116.50M	146.98M
Adjusted Diluted Earnings per Share	$0.05	$0.26	$0.11	$0.56	($0.28)	($0.24)	($0.77)	($0.15)	($0.33)	$0.37	$0.28
Adjusted Weighted Average Diluted Shares Outstanding	113.30M	113.63M	112.44M	116.11M	105.60M	106.95M	108.26M	110.35M	112.91M	145.96M	149.05M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	($0.24)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	106.59M	107.81M	108.84M	106.10M	107.10M	106.60M	111.26M	112.36M	114.08M	146.96M	147.37M
Normalized Net Operating Profit after Tax (NOPAT)	6.26	17	0.63	32	-2.75	-14	-31	-4.90	-10	26	43
Normalized NOPAT Margin	5.30%	9.11%	0.29%	10.08%	-0.76%	-4.85%	-12.51%	-2.02%	-3.85%	8.08%	12.46%
Pre Tax Income Margin	5.97%	12.96%	0.25%	14.04%	-0.95%	-8.55%	-24.79%	-4.98%	-7.37%	9.53%	16.42%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	147.92	283.30	0.00	519.25	0.00	-4.43	-2.81	-1.42	0.00	0.00	0.00
NOPAT to Interest Expense	130.47	343.61	0.00	762.72	0.00	-3.15	-1.97	-0.99	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	94.63	215.55	0.00	460.33	0.00	-4.81	-3.07	-2.07	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	77.17	275.85	0.00	703.80	0.00	-3.52	-2.23	-1.64	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	90.23%	136.79%	2,661.03%	105.46%	-25.26%	0.00%	-15.16%	0.00%	0.00%	16.34%	0.00%

This table displays calculated financial ratios and metrics derived from MiMedx Group's official financial filings.

Metric	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025
Period end date	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	46.37%	21.70%	21.49%	20.72%	16.75%	18.18%	7.32%	2.87%	7.00%	4.13%	13.07%
EBITDA Growth	369.26%	108.42%	236.23%	306.21%	33.51%	1,925.47%	110.09%	1.51%	-14.56%	-17.76%	-36.63%
EBIT Growth	779.32%	96.37%	212.15%	256.46%	37.14%	3,975.44%	114.80%	0.25%	-30.06%	-38.12%	-47.15%
NOPAT Growth	305.51%	96.34%	261.99%	309.71%	406.29%	4,504.13%	62.90%	-26.15%	-87.20%	-35.81%	-48.61%
Net Income Growth	-118.69%	52.49%	111.04%	201.28%	13,017.15%	285.85%	1,368.75%	-5.14%	-86.09%	-24.17%	-45.43%
EPS Growth	-300.00%	45.45%	109.09%	166.67%	1,900.00%	200.00%	1,100.00%	-16.67%	-86.11%	-16.67%	-50.00%
Operating Cash Flow Growth	-74.01%	60.40%	358.74%	1,233.79%	282.38%	247.68%	180.57%	53.42%	83.11%	-11.36%	-33.90%
Free Cash Flow Firm Growth	207.98%	72.77%	142.75%	67.43%	-66.78%	-1,070.92%	-857.46%	-1,408.57%	252.72%	134.42%	131.73%
Invested Capital Growth	5.86%	7.67%	9.62%	27.77%	95.85%	104.77%	101.06%	85.12%	-2.00%	-9.48%	-3.69%
Revenue Q/Q Growth	9.88%	-3.63%	13.37%	0.56%	6.27%	-2.45%	2.95%	-3.61%	10.53%	-5.06%	11.79%
EBITDA Q/Q Growth	299.67%	-94.46%	1,583.12%	6.62%	29.27%	-16.93%	74.58%	-48.48%	8.81%	-15.96%	34.89%
EBIT Q/Q Growth	259.20%	-102.99%	3,297.34%	2.83%	39.55%	-17.18%	77.21%	-52.01%	-2.64%	-25.27%	51.36%
NOPAT Q/Q Growth	326.86%	-102.11%	4,690.93%	-4.57%	447.69%	-81.71%	69.80%	-56.73%	-5.09%	-7.94%	35.94%
Net Income Q/Q Growth	95.09%	-1,103.62%	124.08%	611.17%	526.63%	-82.68%	90.31%	-54.07%	-8.12%	-5.58%	36.95%
EPS Q/Q Growth	77.78%	-200.00%	116.67%	500.00%	500.00%	-83.33%	100.00%	-58.33%	0.00%	0.00%	20.00%
Operating Cash Flow Q/Q Growth	-686.44%	28.02%	292.07%	64.51%	-19.81%	-41.72%	264.90%	-10.04%	-4.29%	-71.79%	172.11%
Free Cash Flow Firm Q/Q Growth	189.32%	-157.22%	221.51%	-152.44%	191.11%	-1,967.41%	21.40%	-4.45%	121.30%	96.82%	-27.55%
Invested Capital Q/Q Growth	17.69%	9.30%	-3.27%	2.69%	80.39%	14.28%	-5.02%	-5.45%	-4.51%	5.56%	1.05%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	80.68%	82.67%	83.28%	81.90%	84.06%	84.67%	82.97%	81.77%	81.80%	81.23%	81.05%
EBITDA Margin	16.05%	0.96%	14.23%	15.09%	18.36%	16.43%	27.86%	14.89%	14.66%	12.97%	15.66%
Operating Margin	15.21%	-0.47%	13.34%	13.61%	17.84%	15.58%	26.89%	13.28%	11.90%	9.35%	12.55%
EBIT Margin	15.20%	-0.47%	13.30%	13.60%	17.86%	15.46%	26.62%	13.25%	11.68%	9.19%	12.44%
Profit (Net Income) Margin	-0.56%	-6.95%	1.48%	10.44%	61.59%	10.93%	20.21%	9.63%	8.01%	7.96%	9.75%
Tax Burden Percent	-4.20%	263.51%	13.08%	90.47%	384.34%	81.17%	75.92%	70.89%	66.12%	81.55%	73.94%
Interest Burden Percent	87.18%	559.47%	84.92%	84.88%	89.72%	87.10%	100.01%	102.50%	103.72%	106.24%	106.02%
Effective Tax Rate	0.28%	0.00%	-0.81%	6.27%	-268.61%	20.58%	24.10%	31.01%	33.88%	18.45%	26.06%
Return on Invested Capital (ROIC)	73.60%	-1.56%	69.13%	71.79%	251.81%	43.78%	76.92%	35.75%	24.94%	22.21%	28.49%
ROIC Less NNEP Spread (ROIC-NNEP)	114.85%	22.20%	113.38%	78.44%	266.54%	49.71%	77.43%	34.95%	24.72%	21.71%	27.85%
Return on Net Nonoperating Assets (RNNOA)	-38.97%	-5.56%	-31.40%	-26.78%	-60.48%	-8.89%	-20.99%	-12.61%	-8.52%	-7.05%	-10.70%
Return on Equity (ROE)	34.63%	-7.11%	37.73%	45.01%	191.32%	34.89%	55.93%	23.14%	16.42%	15.16%	17.79%
Cash Return on Invested Capital (CROIC)	-24.37%	-14.13%	16.28%	34.23%	32.52%	26.91%	37.73%	43.46%	41.23%	42.61%	29.85%
Operating Return on Assets (OROA)	22.66%	-0.77%	22.74%	23.23%	27.97%	26.54%	44.58%	20.99%	16.20%	13.16%	17.37%
Return on Assets (ROA)	-0.83%	-11.39%	2.53%	17.84%	96.47%	18.76%	33.85%	15.25%	11.11%	11.40%	13.61%
Return on Common Equity (ROCE)	-3.71%	1.13%	-6.24%	-4.91%	109.86%	20.88%	35.06%	15.35%	16.42%	15.16%	17.79%
Return on Equity Simple (ROE_SIMPLE)	0.00%	137.59%	99.66%	326.09%	0.00%	46.54%	52.90%	48.87%	0.00%	19.82%	0.00%
Net Operating Profit after Tax (NOPAT)	11	-0.24	11	10	57	10	18	7.70	7.31	6.73	9.15
NOPAT Margin	15.17%	-0.33%	13.45%	12.76%	65.77%	12.37%	20.41%	9.16%	7.87%	7.63%	9.28%
Net Nonoperating Expense Percent (NNEP)	-41.25%	-23.76%	-44.25%	-6.65%	-14.73%	-5.93%	-0.52%	0.80%	0.22%	0.51%	0.64%
Return On Investment Capital (ROIC_SIMPLE)	36.86%	-	-	-	29.77%	-	-	-	3.43%	3.04%	3.89%
Cost of Revenue to Revenue	19.32%	17.33%	16.72%	18.10%	15.94%	15.33%	17.03%	18.23%	18.20%	18.77%	18.95%
SG&A Expenses to Revenue	67.01%	72.90%	63.94%	64.34%	62.59%	65.08%	63.53%	63.67%	65.70%	67.99%	65.06%
R&D to Revenue	-6.36%	4.86%	4.52%	3.76%	2.80%	3.35%	3.45%	3.47%	3.84%	3.77%	3.35%
Operating Expenses to Revenue	65.47%	83.15%	69.94%	68.29%	66.22%	69.09%	56.08%	68.49%	69.90%	71.87%	68.51%
Earnings before Interest and Taxes (EBIT)	11	-0.34	11	11	16	13	23	11	11	8.11	12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	12	0.69	12	12	16	14	24	13	14	11	15
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	636.42	7.15	5.75	6.09	4.79	7.32	5.52	4.17
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	8.65	7.24	7.49	5.77	8.72	6.50	4.87
Price to Revenue (P/Rev)	1.18	1.39	2.59	2.74	3.17	2.68	3.00	2.53	4.05	3.18	2.48
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	17.53	6.36	6.83	5.78	33.33	27.87	28.05
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	5.71%	15.73%	14.65%	17.31%	3.00%	3.59%	3.57%
Enterprise Value to Invested Capital (EV/IC)	6.89	7.56	13.94	14.71	8.88	6.83	8.08	7.02	12.20	8.98	6.90
Enterprise Value to Revenue (EV/Rev)	1.46	1.67	2.84	2.93	3.07	2.59	2.86	2.34	3.81	2.93	2.20
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	44.81	24.52	24.38	15.98	14.56	11.92	20.66	16.68	16.33
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	57.03	27.57	26.63	17.16	15.50	12.72	22.80	19.36	18.93
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	57.27	28.16	12.09	9.59	10.29	8.83	30.81	26.11	25.95
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	83.23	36.89	23.56	19.18	13.88	20.08	15.75	13.80
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	89.58	48.22	36.17	34.08	28.61	20.97	29.30	20.01	22.68
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.65	0.65	0.61	0.52	0.34	0.12	0.13	0.12	0.10	0.09	0.09
Long-Term Debt to Equity	0.65	0.65	0.61	0.52	0.34	0.12	0.11	0.10	0.09	0.09	0.08
Financial Leverage	-0.34	-0.25	-0.28	-0.34	-0.23	-0.18	-0.27	-0.36	-0.34	-0.32	-0.38
Leverage Ratio	2.15	2.15	2.17	2.17	1.89	1.69	1.64	1.58	1.50	1.37	1.36
Compound Leverage Factor	1.88	12.01	1.85	1.84	1.70	1.47	1.64	1.61	1.55	1.46	1.44
Debt to Total Capital	39.48%	39.52%	37.96%	34.29%	25.60%	11.10%	11.32%	10.78%	9.49%	8.43%	7.85%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.52%	0.57%	1.69%	1.90%	1.13%	0.51%	0.53%
Long-Term Debt to Total Capital	39.48%	39.52%	37.96%	34.29%	25.08%	10.53%	9.63%	8.88%	8.36%	7.92%	7.32%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	75.14%	75.04%	71.89%	64.78%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-14.61%	-14.56%	-9.84%	0.93%	74.40%	88.90%	88.68%	89.22%	90.51%	91.57%	92.15%
Debt to EBITDA	-4.55	-35.43	2.62	1.32	1.21	0.36	0.32	0.33	0.31	0.30	0.38
Net Debt to EBITDA	1.62	9.10	-1.06	-0.87	-0.81	-0.54	-0.71	-1.00	-1.31	-1.42	-2.04
Long-Term Debt to EBITDA	-4.55	-35.43	2.62	1.32	1.19	0.34	0.27	0.27	0.28	0.28	0.35
Debt to NOPAT	-4.71	-12.07	3.34	1.52	0.60	0.22	0.23	0.24	0.47	0.47	0.60
Net Debt to NOPAT	1.68	3.10	-1.36	-1.00	-0.40	-0.32	-0.50	-0.74	-1.95	-2.22	-3.25
Long-Term Debt to NOPAT	-4.71	-12.07	3.34	1.52	0.59	0.20	0.19	0.20	0.41	0.44	0.56
Altman Z-Score	2.80	3.16	5.73	6.48	7.73	9.59	11.63	9.91	13.62	11.60	9.00
Noncontrolling Interest Sharing Ratio	110.72%	115.90%	116.55%	110.91%	42.58%	40.17%	37.32%	33.65%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.08	3.22	3.18	3.54	3.57	3.29	3.85	4.10	4.21	4.70	4.39
Quick Ratio	2.50	2.59	2.65	2.98	2.95	2.50	3.05	3.41	3.51	3.96	3.74
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	8.14	-4.66	5.66	-2.97	2.70	-55	-43	-45	9.54	19	14
Operating Cash Flow to CapEx	-843.18%	-639.49%	2,600.33%	2,036.78%	2,402.11%	97.30%	4,631.42%	11,476.02%	0.00%	1,405.57%	8,055.31%
Free Cash Flow to Firm to Interest Expense	0.00	-3.00	0.00	0.00	0.00	-32.26	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	-2.61	0.00	0.00	0.00	3.54	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	-3.01	0.00	0.00	0.00	-0.10	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.49	1.64	1.71	1.71	1.57	1.72	1.67	1.58	1.39	1.43	1.40
Accounts Receivable Turnover	6.42	6.81	6.81	6.88	6.63	6.58	6.69	6.65	6.36	5.91	5.96
Inventory Turnover	3.93	3.65	3.48	3.34	3.19	2.82	2.70	2.63	2.68	2.62	2.70
Fixed Asset Turnover	31.47	0.00	0.00	41.19	43.36	44.89	48.35	50.62	54.01	53.74	59.58
Accounts Payable Turnover	6.10	6.37	6.48	6.13	6.24	6.30	7.17	7.08	7.30	6.86	8.38
Days Sales Outstanding (DSO)	56.85	53.57	53.59	53.05	55.04	55.49	54.55	54.85	57.38	61.79	61.22
Days Inventory Outstanding (DIO)	92.81	99.97	104.85	109.33	114.26	129.30	135.31	138.68	136.19	139.14	135.10
Days Payable Outstanding (DPO)	59.83	57.28	56.34	59.52	58.46	57.92	50.91	51.52	50.00	53.24	43.55
Cash Conversion Cycle (CCC)	89.84	96.26	102.10	102.86	110.83	126.87	138.95	142.01	143.57	147.70	152.76
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	57	62	60	62	111	127	121	114	109	115	116
Invested Capital Turnover	4.85	4.69	5.14	5.63	3.83	3.54	3.77	3.90	3.17	2.91	3.07
Increase / (Decrease) in Invested Capital	3.14	4.42	5.27	13	54	65	61	52	-2.23	-12	-4.45
Enterprise Value (EV)	391	469	837	907	988	867	975	801	1,329	1,032	802
Market Capitalization	316	389	764	846	1,021	896	1,023	868	1,414	1,120	902
Book Value per Share	($0.16)	($0.16)	($0.11)	$0.01	$1.23	$1.06	$1.14	$1.23	$1.31	$1.38	$1.47
Tangible Book Value per Share	($0.38)	($0.38)	($0.33)	($0.20)	$1.01	$0.85	$0.93	$1.02	$1.10	$1.17	$1.25
Total Capital	123	123	129	143	192	175	189	203	213	221	235
Total Debt	49	49	49	49	49	19	21	22	20	19	18
Total Long-Term Debt	49	49	49	49	48	18	18	18	18	18	17
Net Debt	-17	-13	-20	-32	-33	-29	-48	-67	-84	-88	-100
Capital Expenditures (CapEx)	0.67	0.63	0.30	0.63	0.43	6.14	0.47	0.17	-5.10	0.38	0.18
Debt-free, Cash-free Net Working Capital (DFCFNWC)	25	30	28	30	37	49	48	45	44	52	53
Debt-free Net Working Capital (DFNWC)	91	91	97	111	119	98	117	134	149	159	172
Net Working Capital (NWC)	91	91	97	111	118	97	114	130	146	157	171
Net Nonoperating Expense (NNE)	12	4.75	9.73	1.89	3.63	1.22	0.17	-0.39	-0.13	-0.29	-0.47
Net Nonoperating Obligations (NNO)	-18	-13	-20	-32	-32	-29	-47	-67	-84	-88	-100
Total Depreciation and Amortization (D&A)	0.63	1.03	0.76	1.22	0.43	0.82	1.08	1.37	2.77	3.34	3.17
Debt-free, Cash-free Net Working Capital to Revenue	9.22%	10.55%	9.53%	9.61%	11.59%	14.69%	14.15%	13.20%	12.70%	14.81%	14.56%
Debt-free Net Working Capital to Revenue	33.84%	32.37%	32.80%	35.88%	37.10%	29.19%	34.42%	39.11%	42.63%	45.01%	47.24%
Net Working Capital to Revenue	33.84%	32.37%	32.80%	35.88%	36.78%	28.89%	33.49%	37.98%	41.93%	44.69%	46.89%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.02)	($0.06)	$0.00	$0.06	$0.40	$0.06	$0.12	$0.05	$0.06	$0.05	$0.07
Adjusted Weighted Average Basic Shares Outstanding	112.91M	114.40M	115.87M	116.30M	116.50M	146.40M	147.33M	146.96M	146.98M	147.27M	147.76M
Adjusted Diluted Earnings per Share	($0.02)	($0.06)	$0.00	$0.06	$0.36	$0.06	$0.12	$0.05	$0.05	$0.05	$0.06
Adjusted Weighted Average Diluted Shares Outstanding	112.91M	114.40M	115.87M	119.33M	145.96M	150.03M	148.90M	148.37M	149.05M	149.68M	149.32M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	114.08M	115.60M	116.11M	116.38M	146.96M	147.60M	146.81M	146.95M	147.37M	147.70M	147.96M
Normalized Net Operating Profit after Tax (NOPAT)	11	-0.24	7.59	10	11	11	18	7.91	7.37	6.73	9.15
Normalized NOPAT Margin	15.17%	-0.33%	9.34%	12.76%	12.49%	12.42%	20.41%	9.41%	7.93%	7.63%	9.28%
Pre Tax Income Margin	13.25%	-2.64%	11.29%	11.54%	16.02%	13.47%	26.62%	13.58%	12.11%	9.76%	13.19%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	-0.22	0.00	0.00	0.00	7.75	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	-0.15	0.00	0.00	0.00	6.20	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	-0.63	0.00	0.00	0.00	4.12	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	-0.56	0.00	0.00	0.00	2.57	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	16.34%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Key Financial Trends

MiMedx Group (NASDAQ: MDXG) Financial Summary – Past Four Years Analysis

MiMedx Group has shown a general trend of improving operational performance and cash flow management over the past four years, highlighted by positive net income and growing revenues in recent quarters. However, the company still faces challenges including elevated liabilities and fluctuations in expenses.

Net income from continuing operations has improved significantly, rising from losses in early 2023 to $9.6 million in Q2 2025, indicating improved profitability.
Operating revenues increased steadily, reaching nearly $98.6 million in Q2 2025 from about $67 million in Q2 2022, reflecting top-line growth.
Gross profit margins have improved as total gross profit increased to $79.9 million in Q2 2025 from $55 million in Q2 2022, showing better cost control in production.
Net cash provided by operating activities rose to $14.4 million in Q2 2025 compared to $7.8 million in Q1 2024 and $7.7 million in Q2 2022, demonstrating stronger cash generation from core operations.
Cash and equivalents increased to $118.9 million by Q2 2025 from $68.7 million in Q2 2022, bolstering liquidity and financial stability.
Capital expenditures have remained relatively low, with property, plant, and equipment purchases modestly trending around $0.1 – 0.5 million per quarter, indicating controlled investment spending.
The company maintains goodwill and intangible assets at stable levels, around $19 million and $11-12 million, showing a steady intangible asset base.
Total liabilities increased to $74.5 million in Q2 2025 from $62 million in Q1 2024 and $37 million in Q2 2022, indicating growing debt and obligations.
Employee benefit liabilities and accrued expenses remain high, contributing to current liabilities exceeding $50 million in Q2 2025, which could pressure near-term liquidity.
Operating expenses, including selling, general and administrative (SG&A), have risen from roughly $55 million in Q2 2022 to $64 million in Q2 2025, potentially impacting net margins if revenue growth slows.

Overview: MiMedx Group has demonstrated clear improvement in profitability and cash flow generation over the last several years, supported by rising revenues and better gross margins. The company has strengthened its liquidity position with increasing cash reserves. On the downside, the growth in liabilities, sustained high employment-related liabilities, and rising operating expenses present ongoing challenges to margin expansion and financial flexibility. Investors should watch future quarters for continued revenue growth and effective expense management to sustain profitability trends.

09/16/25 10:26 AM ETAI Generated. May Contain Errors.

Financials Breakdown Chart

Frequently Asked Questions About MiMedx Group's Financials

When does MiMedx Group's fiscal year end?

According to the most recent income statement we have on file, MiMedx Group's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has MiMedx Group's net income changed over the last 10 years?

MiMedx Group's net income appears to be on an upward trend, with a most recent value of $42.42 million in 2024, rising from $6.22 million in 2014. The previous period was $58.23 million in 2023. See MiMedx Group's forecast for analyst expectations on what’s next for the company.

What is MiMedx Group's operating income?

MiMedx Group's total operating income in 2024 was $58.87 million, based on the following breakdown:

Total Gross Profit: $288.81 million
Total Operating Expenses: $229.94 million

How has MiMedx Group's revenue changed over the last 10 years?

Over the last 10 years, MiMedx Group's total revenue changed from $118.22 million in 2014 to $348.88 million in 2024, a change of 195.1%.

How much debt does MiMedx Group have?

MiMedx Group's total liabilities were at $70.81 million at the end of 2024, a 26.5% decrease from 2023, and a 255.3% increase since 2014.

How much cash does MiMedx Group have?

In the past 10 years, MiMedx Group's cash and equivalents has ranged from $27.48 million in 2017 to $104.42 million in 2024, and is currently $104.42 million as of their latest financial filing in 2024.

How has MiMedx Group's book value per share changed over the last 10 years?

Over the last 10 years, MiMedx Group's book value per share changed from 0.84 in 2014 to 1.31 in 2024, a change of 57.3%.

Related Companies

This page (NASDAQ:MDXG) was last updated on 9/16/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MiMedx Group (MDXG) Financials

Key Financial Trends

Financials Breakdown Chart

Frequently Asked Questions About MiMedx Group's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MiMedx Group (MDXG) Financials

Annual Income Statements for MiMedx Group

Quarterly Income Statements for MiMedx Group

Annual Cash Flow Statements for MiMedx Group

Quarterly Cash Flow Statements for MiMedx Group

Annual Balance Sheets for MiMedx Group

Quarterly Balance Sheets for MiMedx Group

Annual Metrics And Ratios for MiMedx Group

Quarterly Metrics And Ratios for MiMedx Group

Key Financial Trends

Financials Breakdown Chart

Frequently Asked Questions About MiMedx Group's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools